A laboratory study demonstrates how a new targeted drug, Elesclomol, blocks oxidative phosphorylation, which appears to play essential role in melanoma that has not been well understood. Elesclomol was previously shown to have clinical benefit only in patients with normal serum lactate dehydrogenase, a laboratory test routinely used to assess activity of disease.